Online Disruptive 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 07, 2016
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Trading Symbol	odt
Entity Registrant Name	ONLINE DISRUPTIVE TECHNOLOGIES, INC.
Entity Central Index Key	1,498,380
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		114,180,828
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 621,258	$ 1,206,809
Prepaid expenses	1,728	2,651
VAT Receivable	28,718	22,208
Total Current Assets	651,704	1,231,668
Restricted cash	13,329	12,814
Fixed Assets	68,331	58,321
Total Assets	733,364	1,302,803
Current Liabilities
Accounts Payable	107,220	54,674
Accrued Liabilities	157,905	72,117
Total Current Liabilities	265,125	126,791
Convertible debentures	500,950	380,199
Total Liabilities	766,075	506,990
EQUITY
Authorized: 20,000,000 Preferred Shares, par value $0.001 500,000,000 Common Shares, par value $0.001 Issued and outstanding: Nil Preferred Shares 108,637,721 Common Shares (December 31, 2015: 98,979,174 Common Shares)	114,181	98,979
Additional Paid-in Capital	9,374,398	8,700,219
Accumulated Other Comprehensive Loss	(83,931)	(88,720)
Deficit	(9,483,096)	(8,026,578)
Equity Attributable to Shareholders of the Company	(78,448)	683,900
Non-Controlling Interests	45,737	111,913
Total Equity	(32,711)	795,813
Total Liabilities and Equity	$ 733,364	$ 1,302,803

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Par Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Issued	108,637,721	98,979,174
Common Stock, Shares, Outstanding	108,637,721	98,979,174

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
General and Administrative Expenses
Accounting Fees	$ 7,500	$ 7,500	$ 22,500	$ 20,750
Audit & Tax Fees	1,040	5,230	55,600	37,330
Bank Fees	194	205	436	689
Consulting Fees	107,272	197,043	291,216	521,881
Filing and Transfer Agent Fees	1,832	3,223	9,561	7,942
Insurance Expense	1,628	9,507	43,216	48,213
Legal Fees	8,931	19,812	33,933	49,738
Marketing Expense	0	70	0	31,757
Office and Miscellaneous Expense	23,834	4,776	55,109	7,704
Payroll Expense	8,067	0	18,981	0
Rent Expense	14,979	0	41,896	0
Research and Development Expense	223,385	80,609	728,605	723,721
Stock-Based Compensation	85,944	44,426	236,350	324,302
Travel Expense	4,611	10,502	11,305	17,884
Total General and Administrative Expenses	(489,217)	(382,903)	(1,548,708)	(1,791,911)
Other Expense
Interest Accretion	(47,232)	(68,493)	(120,751)	(129,955)
Interest Expense	(679)	0	(806)	0
Foreign Currency Gain (Loss)	11,006	22,759	5,117	(31,092)
Net (Loss) for the period	(526,122)	(428,637)	(1,665,148)	(1,952,958)
Other Comprehensive Income
Currency translation adjustments	8,714	(26,581)	4,787	7,828
Comprehensive (Loss) for the period	(517,408)	(455,218)	(1,660,361)	(1,945,130)
Net (Loss) attributable to:
Common Stockholders	(469,723)	(389,607)	(1,456,518)	(1,703,970)
Non-Controlling Interests	(56,399)	(39,030)	(208,630)	(248,988)
Net loss for the period	(526,122)	(428,637)	(1,665,148)	(1,952,958)
Net Comprehensive (Loss) Attributable to:
Common Stockholders	(462,215)	(409,502)	(1,452,411)	(1,698,110)
Non-Controlling Interests	(55,193)	(45,716)	(207,950)	(247,020)
Comprehansive Income Loss for the Period	$ (517,408)	$ (455,218)	$ (1,660,361)	$ (1,945,130)
Basic and Diluted Net Loss per Common Share	$ 0	$ (0.01)	$ (0.02)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	111,386,865	88,238,860	106,187,504	95,670,026

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flow from Operating Activities
Net loss for the period	$ (1,665,148)	$ (1,952,958)
Adjustment for items not involving cash:
Stock-Based Compensation	236,350	324,302
Foreign exchange gain/loss	(5,118)	31,092
Depreciation - fixed assets	0	5,058
Interest expense	0	0
Interest accretion	120,751	129,955
Changes in non-cash working capital items:
Increase in VAT receivable	(5,486)	(72,781)
Decrease in prepaid expense	1,005	0
Increase in accounts payable and accrued liabilities	132,555	254,184
Net cash (used in) operating activities	(1,185,091)	(1,281,148)
Cash flow from financing activities
Share subscription received	625,500	1,800,812
Common shares issued by subsidiary	0	708,483
Net cash provided by financing activities	625,500	2,509,295
Cash flow used in investing activities
Cash utilized in purchase of assets	(7,485)	(37,881)
Net cash used in investing activities	(7,485)	(37,881)
Effects of exchange rate changes on cash and cash equivalents	(18,475)	(65,766)
Net (decrease) increase in cash	(585,551)	1,124,500
Cash, beginning of period	1,206,809	329,855
Cash, end of period	621,258	1,454,355
Supplementary Information
Interest Paid	0	0
Income Taxes Paid	$ 0	$ 0

Nature of Operations and Going

Nature of Operations and Going Concern	9 Months Ended
	Sep. 30, 2016
Nature of Operations and Going Concern [Text Block]	Note 1 - Nature of Operations and Going Concern Online Disruptive Technologies, Inc. (“ODT” or the “Company”) was incorporated on November 16, 2009 in the State of Nevada, U.S.A. The Company was in the business of operating websites with advertising revenue platforms. However, as described below, the Company changed its primary business focus to the development and commercialization of a biotechnology platform. The Company has limited operations and has had no revenues from inception to date. The Company has a December 31 year-end. Effective March 24, 2010, the Company acquired 100% of the issued and outstanding shares of RelationshipScoreboard.com Entertainment Inc. (“RS” or “RelationshipScoreboard.com”), a company incorporated on November 16, 2009 in the state of Nevada, U.S.A. in exchange for 16,000,000 shares of the Company’s common stock. Upon the completion of the acquisition, the former sole shareholder of RS held 89% of the Company’s issued and outstanding common stock. As a result, the transaction was accounted for as a reverse takeover transaction (“RTO”) for accounting purpose, as RS was deemed to be the acquirer, and these consolidated financial statements are a continuation of the financial statements of RS. On January 28, 2013, RelationshipScoreboard.com was closed and dissolved. The Company sold the website assets for $10 to an arm’s length individual and wrote off all supplier payables in the amount of $430. On April 23, 2012, the Company established an Israeli subsidiary named Savicell Diagnostic Ltd. (“Savicell”) with the intention of exploring business ventures in the biotechnology sector. On July 25, 2012, Savicell entered into a definitive licensing agreement with a division of Tel Aviv University for the purpose of developing and commercializing a new technology relative to the early detection of various forms of disease. With the consummation of this transaction, the Company is now entirely focused on its biotechnology efforts. These consolidated financial statements have been prepared with the ongoing assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has positive working capital of $386,579 as at September 30, 2016 (December 31, 2015 – $1,104,876) and an accumulated deficit of $9,483,096. Furthermore, additional future losses are anticipated which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The operations of the Company have primarily been funded by the sale of common shares and loans received. Continued operations of the Company are dependent on the Company’s ability to complete equity financings or to generate profitable operations in the future. Management’s plan in this regard is to secure additional funds through future equity financings. Such financings may not be available or may not be available on reasonable terms to the Company. Failure to obtain the ongoing support of its equity financings and creditors may make the going concern basis of accounting inappropriate, in which case the Company’s assets and liabilities would need to be recognized at their liquidation values. These consolidation financial statements do not include any adjustments relating to the recoverability and classification of recorded assets amounts and classification of liabilities that might arise from this uncertainty.

Significant Accounting Policies

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Significant Accounting Policies [Text Block]	Note 2 - Significant Accounting Policies a) Basis of Presentation These interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and should be read in conjunction with those annual consolidated financial statements filed for the year ended December 31, 2015. In the opinion of management, these interim consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments for a fair presentation of the interim consolidated financial statements. All significant inter-company accounts and transactions have been eliminated on consolidation. The results of operations for any interim period are not necessarily indicative of results for the full year. For further information, refer to the Company’s consolidated financial statements and notes thereto filed on April 14, 2016 for the year ended December 31, 2015. b) Principles of Consolidation c) Use of Estimates Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred income tax assets and determination of useful lives of property, plant and equipment. d) Foreign Currency Translation The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). All transactions are recorded in NIS. Monetary assets and liabilities denominated in NIS are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates and expenses are translated at the average exchange rates. Gains and losses from such translations are included in stockholders’ equity, as a component of other comprehensive income. In the year ended 2013, Savicell’s functional currency was the U.S. dollar. During the year 2014, with the increased volume of transactions in the local currency, management reassessed Savicell’s functional currency to NIS based on the change in facts and effective as of January 1, 2014. Such change is still appropriate in year 2016. As a result of the functional currency change discussed above, a cumulative translation adjustment of $4,787 is included in accumulated other comprehensive income and will only be adjusted in the event of a full or partial disposition of the Company's investment in Savicell. e) Cash and Cash Equivalents f) Stock-based Compensation Share-based payments issued to non-employees are recorded at their fair values at each reporting date, as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on a straight-line basis. g) Income Taxes Per FASB ASC 740 “Income taxes” under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At September 30, 2016, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as Interest Expense. h) Comprehensive Income (Loss) i) Earnings (Loss) Per Share Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the quarters ended September 30, 2016 and 2015 because the inclusion of such underlying shares would have had an anti-dilutive effect. j) Financial Instruments and Fair Value of Financial Instruments • Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at September 30, 2016, the fair value of cash and restricted cash measured using Level 1 inputs. The Company’s financial instruments are cash, restricted cash, accounts payable and accrued liabilities and convertible debentures. The recorded values of cash and accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments. k) Research and Development Costs l) Fixed Assets m) Convertible debentures n) Modifications to debt o) Recently Adopted Accounting Pronouncements In January 2015, the FASB issued ASU 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20), Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, which eliminates the concept of extraordinary items. Under this new guidance, entities will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendments in this update are effective for annual and interim periods beginning after December 15, 2015. The Company adopted ASU 2015-01 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's interim consolidated financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis"("ASU 2015-02"). ASU 2015-02 makes several modifications to the consolidation guidance for variable interest entities ("VIEs") and general partners' investments in limited partnerships, as well as modifications to the evaluation of whether limited partnerships are VIEs or voting interest entities. It is effective for annual and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted ASU 2015-02 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's interim consolidated financial position or results of operations. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). In August 2015, FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (“ASU 2015-15”). ASU 2015-03 will require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the debt. ASU 2015-15 allows an entity to present debt issuance costs associated with a revolving line of credit arrangement as an asset, regardless of whether a balance is outstanding. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03 or ASU 2015-15. These ASU’s are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, with early adoption permitted. ASU 2015-03 will require the Company to reclassify its deferred financing costs associated with its long-term debt from other assets to long-term debt on a retrospective basis. The new standard will not affect the Company’s results of operations or cash flows. The Company adopted ASU 2015-15 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's interim consolidated financial position or results of operations. p) Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This accounting standard supersedes all existing US GAAP revenue recognition guidance. Under ASU 2014-09, a company will recognize revenue when it transfers the control of promised goods or services to customers in an amount that reflects the consideration which the company expects to collect in exchange for those goods or services. ASU 2014-09 will require additional disclosures in the notes to the consolidated financial statements and is effective for annual and interim reporting periods beginning after December 15, 2016. The Company is evaluating the impact of ASU 2014-09 and an estimate of the impact to the interim consolidated financial statements cannot be made at this time. On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting which amends ASC Topic 718, Compensation – Stock Compensation. The ASU simplifies several aspects of the accounting for employee share-based payment transactions. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is evaluating the impact of the amended guidance on its interim consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The ASU provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity's ability to continue as a going concern within one year of the date of issuance of the entity's financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is "substantial doubt about the entity's ability to continue as a going concern." The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter and early adoption is permitted. The Company is evaluating the impact of ASU 2014-15 and an estimate of the impact to the interim consolidated financial statements cannot be made at this time. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This accounting standard supersedes all existing US GAAP revenue recognition guidance. Under ASU 2014-09, a company will recognize revenue when it transfers the control of promised goods or services to customers in an amount that reflects the consideration which the company expects to collect in exchange for those goods or services. ASU 2014-09 will require additional disclosures in the notes to the consolidated financial statements and is effective for annual and interim reporting periods beginning after December 15, 2017. The Company is evaluating the impact of ASU 2014-09 and an estimate of the impact to the consolidated financial statements cannot be made at this time. On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. The ASU simplifies several aspects of the accounting for employee share-based payment transactions. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is evaluating the impact of the amended guidance on its consolidated financial statements. There have been no other accountings pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Text Block]	Note 3 – Property, Plant and Equipment As of September 30, 2016, the fixed assets balance on the financial statement consist of the following: Cost Accumulated Net Book Value Amortization Furniture and Fixtures $ 1,833 $ - $ 1,833 Computer Equipment 24,782 3,769 21,013 Lab Equipment 45,448 2,429 43,019 Foreign Exchange Movement 2,708 242 2,466 Total as of September 30, 2016 $ 74,771 $ 6,440 $ 68,331 Computer Equipment $ 19,139 $ 3,769 $ 15,370 Lab Equipment 45,448 2,429 43,019 Foreign Exchange Movement (74 ) (6 ) (68 ) Total as of December 31, 2015 $ 64,513 $ 6,192 $ 58,321

License and Research Funding Ag

License and Research Funding Agreement	9 Months Ended
	Sep. 30, 2016
License and Research Funding Agreement [Text Block]	Note 4 – License and Research Funding Agreement On July 25, 2012, the Company’s subsidiary Savicell entered into a License and Research Funding Agreement (“R&D Agreement”) with Ramot at Tel Aviv University (“Ramot”) pursuant to which: In the course of research performed at Tel-Aviv University (" TAU Savicell wishes to fund further research at TAU relating to such technology; and Savicell wishes to obtain a license from Ramot with respect to such technology and the results of such further funded research in order to develop and commercialize products in the diagnostics space, and Ramot wishes to grant the Company such license, all in accordance with the terms and conditions of this R&D Agreement. Pursuant to the above noted R&D Agreement, Savicell will fund research expenditures amounting to a total of $1,600,000 according to the following schedule: $81,000 within 5 business days of the R&D Agreement (paid) Before October 2012; $359,500 plus VAT as applicable (paid) Before January 3, 2013; $359,500 plus VAT as applicable (paid) Before April 3, 2013; $400,000 plus VAT as applicable (paid) Before July 3, 2013; $400,000 plus VAT as applicable (paid) The payments originally due on April 3, 2013 and July 3, 2013 were postponed by the parties until such time as the funds were actually required in furtherance of the joint research and development initiatives. As of December 31, 2015, Savicell’s entire financing commitment has been met and no more expenditures are mandated by the R&D Agreement on behalf of Ramot. Savicell is continuing the clinical research within its own laboratory situated in Haifa, Israel. In addition, Savicell issued to Ramot warrants (the “Warrants”) to purchase a number of ordinary shares of Savicell which together comprised 15% of issued shares of Savicell on an as-converted, fully diluted basis (equivalent to 1,765 Warrant Shares of Savicell). The Warrants are exercisable at an exercise price equal to the par value of the Warrant Shares, at any time and from time to time before Savicell completes a deemed liquidity event or the first underwritten offering of the Savicell's ordinary shares to the general public. The fair value of the Warrant Shares was estimated at $1,698.97 per Warrant Share which is equivalent to the price at which Savicell has issued shares to third parties, for a total of $2,998,682 which was included in research and development costs. As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698.97 per share) and the related common shares are considered to be issued and outstanding. Upon successful development and commercialization of the technology, and in recognition of the rights and licenses granted to Savicell pursuant to this R&D Agreement, Savicell will be subject to (a) royalties based on the worldwide sales related to the technology; and (b) minimum annual royalties with respect to any calendar year following the first commercial sales as follows. The minimum annual royalties are subject to increases for each successive year. During the nine months ended September 30, 2016, Savicell incurred $28,050 (2015 - $723,721) of expenses related to kits collaboration with Ramot that have been included in research and development costs.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Text Block]	Note 5– Related Party Transactions The Company completed the following related party transactions: During the nine months ended September 30, 2016, the Company incurred consulting fees and salaries of $450,726 payable to its directors and officers as well as a company controlled by a former director/officer. As at September 30, 2016, included in accounts payable and accrued liabilities are amounts of $24,300 (December 31, 2015 - nil) that was payable to a company controlled by a former director/officer of the Company and $121,842 (December 31, 2015-$16,325) that was payable to current officers or directors of the Company. On November 4, 2011, the Company entered into a loan Agreement (“Loan Agreement”) with a shareholder of the Company to settle a loan payable in the amount of $74,062. Pursuant to the Loan Agreement, the terms of repayment were amended to specify that ten per cent ( 10%) of the gross proceeds of any prospective debt or equity financing undertaken by ODT would be applied to the repayment of the principal of this loan until fully repaid. The term loan is unsecured, non-interest bearing and requires that any balance remaining outstanding on November 4, 2016 would then be fully due and payable.

Convertible debentures

Convertible debentures	9 Months Ended
	Sep. 30, 2016
Convertible debentures [Text Block]	Note 6 – Convertible debentures On April 15, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $852,418. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.055 over a seven year term. On December 31, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $188,085 with an unsecured and non-interest bearing convertible debenture. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven year term. The Company evaluated these convertible debenture for derivatives and determined that they do not qualify for derivative treatment. The Company then evaluated the debenture for beneficial conversion features and determined that some do contain beneficial conversion features. The aggregate intrinsic value of the beneficial conversion features was determined to be $852,418. This amount was recorded as a debt discount on April 15, 2015 that is being amortized over the life of the debenture at effective interest rate of 77%. Total debt discount amortization during the quarter ended September 30, 2016 was $120,751. (September 30, 2015 – $77,472) September 30, 2016 December 31, 2015 Convertible debentures $ 1,040,503 $ 1,040,503 Convertible discount (852,418 ) (852,418 ) Net convertible debentures 188,085 188,085 Interest accretion 312,865 192,114 Balance, as at September 30, 2016 $ 500,950 380,199

Equity

Equity	9 Months Ended
	Sep. 30, 2016
Equity [Text Block]	Note 7 –Equity Common shares On April 19, 2015, the Company issued 3,550,000 common shares at $0.20 per share for total proceeds of $710,000. On May 22, 2015, the Company issued 500,000 common shares at $0.20 per share for total proceeds of $100,000. On May 28, 2015, the Company entered into a debt settlement agreement pursuant to which the Company settled a related party term loan in the aggregate amount of $74,062 by the issuance of 462,890 common shares at $0.20 per share. On June 23 2015, stock options previously granted by the Company were exercised resulting in the issuance of 481,179 common shares at $0.01 per share for total proceeds of $4,812. On June 23, 2015, stock options previously granted by the Company were exercised resulting in the issuance of 100,000 common shares at $0.01 per share for total proceeds of $1,000. On June 25, 2015, the Company issued 5,000,000 common shares at $0.20 per share for total proceeds of $1,000,000. On July 20, 2015, four shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 3,824,922 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $611,987. On September 3, 2015, three shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,786,250 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $285,800. On October 20, 2015, two shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 637,500 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $102,000. As at January 31, 2016, three shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,756,619 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $281,059. On February 28, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 2,198,819 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $351,811. On March 31, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 318,742 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $50,999. On April 18, 2016, the Company issued 625,000 common shares at $0.20 per share for total proceeds of $125,000. On April 21, 2016, two shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 824,992 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $131,999. On April 22, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 318,749 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $50,999. On June 6, 2016, eight shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,115,625 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $178,500. On June 14, 2016, the Company issued 2,500,000 common shares at $0.20 per share for total proceeds of $500,000. On July 5, 2016, stock options previously granted by the Company were exercised resulting in the issuance of 50,000 common shares at $0.01 per share for total proceeds of $500. On July 7, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 839,375 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $134,300. On September 1, 2016, eight shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 4,653,732 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $744,597. For the year ended December 31, 2015, the Company recorded share issue cost of $15,000 for the shares issued. As at September 30, 2016 the Company has 114,180,828 common shares issued and outstanding. Preferred Shares The Company has authorized 20,000,000 preferred shares at a par value of $0.001 per share. No preferred shares have been issued by the Company and accordingly none are outstanding. Stock Options On May 28, 2013, the Company granted a total of 962,358 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share. A quarter of the options will vest on each of the first four anniversaries of the date of initial grant. The options were valued based on the Black Scholes model. On June 22, 2015, 481,179 of these options were exercised at $0.01 per share for total proceeds of $4,812. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $14,752 (September 30, 2015: $106,159) for such options. On August 22, 2013, the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.01 per share. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years from August 22, 2013. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $33,189 (September 30, 2015: $18,827) for such options. On November 11, 2013, the Company granted a total of 1,924,717 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share. A quarter of the options will vest immediately and a quarter on each of the first three anniversaries of the date of initial grant. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $22,934 (September 30, 2015: $141,156) for such options. On January 1, 2014, the Company granted a total of 500,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share. A quarter of the options will vest immediately and a quarter will vest at end of each completed year that the consultant provides the services. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $7,910 (September 30, 2015: $nil) for such options. On May 4, 2014 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share. One third of the options will vest at end of each completed year that the consultant provides the services. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $174 (September 30, 2015: $982) for such options. On May 15, 2014 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share. 25,000 of the options will vest immediately. Furthermore, 75,000 and 50,000 of the options respectively will vest on the first and second anniversaries that the consultant provides the services. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $nil (September 30, 2015: $24,017) for such options. On June 23, 2015, 100,000 of these options were exercised at $0.01 per share for total proceeds of $1,000. In addition, on July 7, 2016, 50,000 of these options were exercised at $0.01 per share for total proceeds of $500. On August 4, 2015 the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest at end of each of June 21, 2016, June 21, 2017 and June 21, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $7,397 for such options. On August 7, 2015 the Company granted a total of 1,730,000 stock options to four advisors of the Company. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest at end of each completed year for which the consultant provides the services. The options were valued based on the Black Scholes model. For year nine months ended September 30, 2016, the Company recorded stock based compensation of $98,785 for such options. On September 1, 2015 the Company granted a total of 150,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest at the grant date of each of September 1, 2015, September 1, 2016 and September 1, 2017 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $12,952 for such options. On November 22, 2015 the Company granted a total of 50,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest at the grant date of each of November 22, 2016, November 22, 2017 and November 22, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $3,114 for such options. On December 1, 2015 the Company granted a total of 125,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest at the grant date of each of December 1, 2016, December 1, 2017 and December 1, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $7,958 for such options. On December 6, 2015 the Company granted a total of 100,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest at the grant date of each of December 6, 2016, December 6, 2017 and December 6, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $7,047 for such options. On February 15, 2016 the Company granted a total of 50,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $2,062 for such options. On March 7, 2016 the Company granted a total of 75,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $2,966 for such options. On May 5, 2016 the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $3,485 for such options. On June 6, 2016 the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.20 per share. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years following June 6, 2016. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company. The options were valued based on the Black Scholes model. For the nine months ended September 30, 2016, the Company recorded stock based compensation of $9,814 for such options. The fair value of each option grant is calculated using the following assumptions: 2016 2015 Expected life – yea 3 - 10 3 - 7 Interest rate 0.73 – 2.22% 0.97 – 2.09% Volatility 65.99 - 99.04% 62.86 – 94.97% Dividend yield - -% - -% Number of Options Weighted Expire date Average Exercise Price Balance, December 31, 2014 14,237,075 $ 0.01 Exercised, on June 23, 2015 (481,179 ) 0.01 Exercised, on June 25, 2015 (100,000 ) 0.01 Granted, on August 4, 2015 150,000 0.20 May 4, 2022 Granted, on August 7, 2015 1,610,000 0.20 August 7, 2022 Granted, on August 25, 2015 120,000 0.20 August 25, 2022 Granted, on September 1, 2015 150,000 0.20 September 1, 2022 Granted, on November 22, 2015 50,000 0.20 November 22, 2022 Granted, on December 1, 2015 125,000 0.20 December 1, 2022 Granted, on December 6, 2015 100,000 0.20 December 6, 2022 Balance, December 31, 2015 15,960,896 $ 0.04 Granted, on February 15, 2016 50,000 0.20 February 15, 2023 Granted, on March 7, 2016 75,000 0.20 March 7, 2023 Granted, on May 5, 2016 150,000 0.20 May 5, 2026 Granted, on June 6, 2016 800,000 0.20 June 6, 2021 Exercised, on July 7, 2016 (50,000 ) 0.01 Balance, September 30, 2016 16,985,896 $ 0.05 Outstanding as at September 30, 2016 Exercisable as at September 30, 2016 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.92 9,750,000 $ 0.01 5.92 0.01 481,179 0.01 1.66 240,589 0.01 1.66 0.01 800,000 0.01 1.89 680,001 0.01 1.89 0.01 1,924,717 0.01 4.12 1,443,538 0.01 4.12 0.01 500,000 0.01 2.25 333,334 0.01 2.25 0.01 150,000 0.01 4.59 100,000 0.01 4.59 0.20 150,000 0.20 4.59 50,000 0.20 4.59 0.20 120,000 0.20 5.90 40,000 0.20 4.90 0.20 1,610,000 0.20 5.85 536,667 0.20 4.85 0.20 150,000 0.20 5.92 50,000 0.20 5.92 0.20 50,000 0.20 6.15 - - - 0.20 125,000 0.20 6.17 - - - 0.20 100,000 0.20 6.19 - - - 0.20 50,000 0.20 6.38 - - - 0.20 75,000 0.20 6.44 50,000 0.2 5.92 0.20 150,000 0.20 9.60 30,000 0.20 9.6 0.20 800,000 0.20 4.68 - - - 16,985,896 $ 0.05 5.25 13,254,129 $ 0.02 5.34 Outstanding as at December 31, 2015 Exercisable as at December 31, 2015 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 6.67 9,750,000 $ 0.01 6.67 0.01 481,179 0.01 2.41 - - - 0.01 800,000 0.01 2.64 453,334 0.01 2.64 0.01 1,924,717 0.01 4.87 1,443,538 0.01 4.87 0.01 500,000 0.01 3.01 333,334 0.01 3.01 0.01 150,000 0.01 5.35 50,000 0.01 5.35 0.01 50,000 0.01 3.37 - - - 0.20 150,000 0.20 5.35 - - - 0.20 120,000 0.20 6.65 - - - 0.20 1,610,000 0.20 6.61 - - - 0.20 150,000 0.20 6.67 50,000 0.20 6.67 0.20 50,000 0.20 6.90 - - - 0.20 125,000 0.20 6.92 - - - 0.20 100,000 0.20 6.94 - - - 15,960,896 $ 0.04 5.97 12,080,205 $ 0.01 6.20 Non-Controlling Interests The Company’s subsidiary, Savicell, granted a third party a warrant certificate to purchase 1,765 common shares of Savicell that initially represented 15% of the underlying common equity of Savicell. In the course of its initial equity issuances up to October 30, 2012 (the “Initial Closing”), Savicell issued a total of 592 ordinary shares at $1,698.97 per share to the non-related third party representing approximately 4.79% of the fully diluted common equity of Savicell for aggregate proceeds of $1,005,795. The Savicell investors are entitled to convert their Savicell shares into common shares of ODT at a price equal to 80% of the per share pricing of the first completed ODT financing of over $500,000 conducted after July 1, 2012 (the “Financing Price”) provided that for purposes of such conversion, the deemed maximum Financing Price shall be the per share price of the common shares of ODT based on (a) an aggregate ODT equity valuation of $30,000,000 ; and (b) the number of common shares of ODT outstanding at the time of the financing. Savicell continued its equity issuances following the Initial Closing. As at December 31, 2012, Savicell had issued a total of 684 shares at $1,698.97 per share representing approximately 5.11% of the fully diluted common equity of Savicell for aggregate proceeds of $1,162,192. During the year ended December 31, 2013, Savicell issued a total of 760 shares at $1,700 per share representing approximately 5.68% of the fully diluted common equity of Savicell for aggregate proceeds of $1,292,000. During the year ended December 31, 2014, Savicell issued a total of 183 shares at $1,699 per share representing approximately 1.37% of the fully diluted common equity of Savicell for aggregate proceeds of $310,977. During the year ended December 31, 2015, Savicell issued a total of 417 shares at $1,700 per share to third parties for aggregate proceeds of $709,087. As at December 31, 2015, Savicell also issued 516 shares at $1,700 to ODT, which of $532,084 has not been received as at December 31, 2015. In addition, Savicell investors exchanged 588 Savicell shares for 6,248,672 of ODT common shares with ODT receiving the Savicell shares so exchanged. Following these share issuances, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 77.00%, 12.6% and 10.4% respectively (December 31, 2014- 74.67%, 13.18% and 12.15%) . During the nine months ended September 30, 2016, Savicell investors exchanged 1132 Savicell shares for 12,026,652 of ODT common shares with ODT receiving the Savicell shares so exchanged. As at September 30, 2016, Savicell received $1,086,018 from ODT and issued 639 shares to ODT in return. Following these share issuances, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 85.78%, 12.01% and 2.21%, respectively (December 31, 2015- 77%, 12.6% and 10.4%) . Savicell’s Common Shares Number Amount of Shares Balance, December 31, 2013 13,209 $ 2,454,192 Issued for cash pursuant to share subscriptions 183 310,977 Balance, December 31, 2014 13,392 2,765,169 Issued for cash pursuant to share subscriptions 730 1,241,171 Shares issued to settle inter-company debts 203 345,198 Share subscription receivable (313 ) (532,084 ) Balance, December 31, 2015 14,012 $ 3,819,454 Shares issued to settle inter-company debts 639 1,086,018 Balance, September 30, 2016 14,651 4,905,472 As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698.97 per share) and the related common shares are considered to be issued and outstanding.

Commitments And Guarantees

Commitments And Guarantees	9 Months Ended
	Sep. 30, 2016
Commitments And Guarantees [Text Block]	Note 8 – Commitments and Guarantees The Company did not become a guarantor to any parties as at September 30, 2016 1. On September 11, 2012, ODT signed an employment agreement with Giora Davidovits, its new chief executive officer and President, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief executive officer, the Company will provide Mr. Davidovits an annual salary of $250,000 together with other benefits and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Giora Davidovits options to purchase 3,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 2. On October 30, 2012, ODT and Savicell signed an employment agreement with Eyal Davidovits, its new chief operating officer, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief operating officer, the Company will provide Mr. Davidovits an annual salary of $112,324 (NIS 432,000), together with other fringe benefits including those related to the use of an automobile, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Eyal Davidovits options to purchase 2,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 3. On November 8, 2012, ODT and Savicell signed an employment agreement with Dr. Irit Arbel, its new vice president, research and development, which agreement entailed an effective date of September 1, 2012. In return for acting as its new vice president, research and development officer, the Company will provide Dr. Arbel an annual salary of $106,084 (NIS 408,000) together with other fringe benefits, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Irit Arbel options to purchase 2,000,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Dr. Arbel is eligible for subsequent option grants at the discretion of the board of directors. 4. On July 20, 2015, the Company signed an operating lease agreement to lease offices for a period ending July 31, 2018 with an option to renew the lease for an additional period of 2 years. The monthly lease expense is $3,152 (NIS 12,121). Future minimum lease commitment under the operating lease agreement is approximately $89,966 (NIS 339,388). The Company pledged a bank deposit which is used as a bank guarantee at an amount of $13,254 (NIS 50,000) to secure its payments under the lease agreement. The Minimum future payments for the above commitments are as follows: Consulting fee and Year Salaries Office rent Total 2016 $ 468,408 $ 37,824 $ 506,232 2017 312,272 37,824 350,096 2018 - 22,064 22,064 Total $ 780,680 $ 97,712 $ 878,392

Geographic Information

Geographic Information	9 Months Ended
	Sep. 30, 2016
Geographic Information [Text Block]	Note 9 - Geographic Information The Company’s head office is located in the United States (“US”). The operations of the Company are primarily in two geographic areas: the US and Israel. A summary of geographical information for the Company’s long lived assets is as follows: Nine month ended September 30, 2016 US Israel Total Long-live assets $ - $ 68,331 $ 68,331 Year ended December 31, 2015 US Israel Total Long-live assets $ - $ 58,321 $ 58,321

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2016
Subsequent Event [Text Block]	Note 10 - Subsequent Event On November 1, 2016, the Company granted a director of the Company 360,000 Stock Options. Each Option entitles the Optionee to acquire one common share in the capital of the Company (each, an “Option Share”) at the exercise price of $0.20 per Option Share until expiry on the date that is ten years after the date of grant. 180,000 of the options are vested immediately and the other180,000 will be vested at the end of year one, provided the Optionee remains director of Savicell Inc.

Restatement

Restatement	9 Months Ended
	Sep. 30, 2016
Restatement [Text Block]	Note 11- Restatement Subsequent to the issuance of certain previously issued financial statements, we determined that there were errors in those financial statements related to the incorrect accounting treatment of convertible debentures which has overstated liabilities, additional paid-in capital and expenses . The effect of the error was material to the financial statements for each of the fiscal quarters ended June 30, 2015 and September 30, 2015 so those quarters will be restated for the effects of the error correction. We have changed our previously issued (i) consolidated balance sheet at June 30, 2015 and September 30, 2015, (ii) consolidated statement of operations and comprehensive income and consolidated statement of cash flows for the periods ended June 30, 2015 and September 30, 2015, and (iii) unaudited financial information for the quarters within fiscal year 2015. We are restating our previously issued unaudited financial information for the fiscal quarters ended June 30, 2015 and September 30, 2015. The following tables summarize the impact of the error correction on our consolidated financial statements, each as compared with the amounts presented in previously issued financial statements. The following tables summarize the as previously reported balances, adjustments, and corrected and restated balances on our consolidated balance sheets by financial statement line item: As at June 30, 2015 (Unaudited) As Reported Adjustment As Restated $ $ $ Total Assets 1,910,811 1,910,811 Convertible debenture (Note 6) 1,257,522 (1,201,366 ) 56,156 Total Liabilities 1,496,543 (1,201,366 ) 295,177 Additional Paid-in Capital 8,360,774 (1,394,865 ) 6,965,909 (Deficit) Accumulated During the Development Stage (10,005,458 ) 2,596,231 (7,409,227 ) Equity Attributable to Shareholders of the Company 252,669 1,201,366 1,454,035 Total Equity 479,484 1,201,366 1,680,850 Total Liabilities and Equity 1,910,811 1,910,811 As at September 30, 2015 (Unaudited) As Reported Adjustment As Restated $ $ $ Total Assets 1,586,164 - 1,586,164 Convertible debenture (Note 6) 1,304,573 (1,180,438 ) 124,135 Total Liabilities 1,496,543 (1,180,438 ) 316,105 Additional Paid-in Capital 10,499,854 (1,394,865 ) 9,104,989 (Deficit) Accumulated During the Development Stage (10,413,168 ) 2,575,303 (7,837,865 ) Equity Attributable to Shareholders of the Company 81,505 1,180,438 1,261,943 Total Equity 89,621 1,180,438 1,270,059 Total Liabilities and Equity 1,586,164 - 1,586,164 The following tables summarize the as previously reported balances, adjustments and corrected and restated balances on our consolidated statements of operations and comprehensive income by financial statement line item for the periods ended: Three months ended June 30, 2015 (Unaudited) As Reported Adjustment As Restated General and Administrative Expenses $ Stock-Based Compensation 2,901,171 (2,621,965 ) 279,206 Other Expense Interest Expense (31,624 ) (25,734 ) (57,358 ) Net (Loss) for the period (3,785,016 ) 2,596,231 (1,188,785 ) Comprehensive Income (Loss) for the period (3,728,937 ) 2,596,231 (1,132,706 ) Net (Loss) attributable to: Common Stockholders (2,783,652 ) 1,786,179 (997,473 ) Non-Controlling Interests (1,001,364 ) 810,052 (191,312 ) (3,785,016 ) 2,596,231 (1,188,785 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (2,742,409 ) 1,785,548 (956,861 ) Non-Controlling Interests (986,528 ) 810,683 (175,845 ) (3,728,937 ) 2,596,231 (1,132,706 ) Basic and Diluted Net Loss per Common Share (0.04 ) (0.01 ) Six months ended June 30, 2015 (Unaudited) As Reported Adjustment As Restated General and Administrative Expenses $ Stock-Based Compensation 2,901,842 (2,621,966 ) 279,876 Other Expense Interest Expense (35,726 ) (25,735 ) (61,461 ) Net (Loss) for the period (4,120,551 ) 2,596,231 (1,524,320 ) Comprehensive Income (Loss) for the period (4,086,144 ) 2,596,231 (1,489,913 ) Net (Loss) attributable to: Common Stockholders (3,030,418 ) 1,731,854 (1,298,564 ) Non-Controlling Interests (1,090,133 ) 864,377 (225,756 ) (4,120,551 ) 2,596,231 (1,524,320 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (3,005,113 ) 1,731,467 (1,273,646 ) Non-Controlling Interests (1,081,031 ) 864,764 (216,267 ) (4,086,144 ) 2,596,231 (1,489,913 ) Basic and Diluted Net Loss per Common Share (0.05 ) - (0.02 ) Three months ended September 30, 2015 (Unaudited) As Reported Adjustment As Restated Other Expense Interest Expense (47,565 ) (20,928 ) (68,493 ) Net (Loss) for the period (407,709 ) (20,928 ) (428,637 ) Comprehensive Income (Loss) for the period (434,290 ) (20,928 ) (455,218 ) Net (Loss) attributable to: Common Stockholders (312,891 ) (76,716 ) (389,607 ) Non-Controlling Interests (94,818 ) 55,788 (39,030 ) (407,709 ) (20,928 ) (428,637 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (332,786 ) (76,716 ) (409,502 ) Non-Controlling Interests (101,504 ) 55,788 (45,716 ) (434,290 ) (20,928 ) (455,218 ) Basic and Diluted Net Loss per Common Share (0.05 ) (0.01 ) Nine months ended September 30, 2015 (Unaudited) As Reported Adjustment As Restated General and Administrative Expenses $ Stock-Based Compensation 2,946,268 (2,621,966 ) 324,302 Other Expense Interest Expense (83,292 ) (46,663 ) (129,955 ) Net (Loss) for the period (4,528,261 ) 2,575,303 (1,952,958 ) Comprehensive Income (Loss) for the period (4,520,433 ) 2,575,303 (1,945,130 ) Net (Loss) attributable to: Common Stockholders (3,397,021 ) 1,693,051 (1,703,970 ) Non-Controlling Interests (1,131,240 ) 882,252 (248,988 ) (4,528,261 ) 2,575,303 (1,952,958 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (3,391,161 ) 1,693,051 (1,698,110 ) Non-Controlling Interests (1,129,272 ) 882,252 (247,020 ) (4,520,433 ) 2,575,303 (1,945,130 ) Basic and Diluted Net Loss per Common Share (0.05 ) (0.02 )

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Basis of Presentation [Policy Text Block]	a) Basis of Presentation These interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and should be read in conjunction with those annual consolidated financial statements filed for the year ended December 31, 2015. In the opinion of management, these interim consolidated financial statements reflect all adjustments, consisting of only normal recurring adjustments for a fair presentation of the interim consolidated financial statements. All significant inter-company accounts and transactions have been eliminated on consolidation. The results of operations for any interim period are not necessarily indicative of results for the full year. For further information, refer to the Company’s consolidated financial statements and notes thereto filed on April 14, 2016 for the year ended December 31, 2015.
Principles of Consolidation [Policy Text Block]	b) Principles of Consolidation
Use of Estimates [Policy Text Block]	c) Use of Estimates Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred income tax assets and determination of useful lives of property, plant and equipment.
Foreign Currency Translation [Policy Text Block]	d) Foreign Currency Translation The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). All transactions are recorded in NIS. Monetary assets and liabilities denominated in NIS are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates and expenses are translated at the average exchange rates. Gains and losses from such translations are included in stockholders’ equity, as a component of other comprehensive income. In the year ended 2013, Savicell’s functional currency was the U.S. dollar. During the year 2014, with the increased volume of transactions in the local currency, management reassessed Savicell’s functional currency to NIS based on the change in facts and effective as of January 1, 2014. Such change is still appropriate in year 2016. As a result of the functional currency change discussed above, a cumulative translation adjustment of $4,787 is included in accumulated other comprehensive income and will only be adjusted in the event of a full or partial disposition of the Company's investment in Savicell.
Cash and Cash Equivalents [Policy Text Block]	e) Cash and Cash Equivalents
Stock-based Compensation [Policy Text Block]	f) Stock-based Compensation Share-based payments issued to non-employees are recorded at their fair values at each reporting date, as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on a straight-line basis.
Income Taxes [Policy Text Block]	g) Income Taxes Per FASB ASC 740 “Income taxes” under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At September 30, 2016, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as Interest Expense.
Comprehensive Income (Loss) [Policy Text Block]	h) Comprehensive Income (Loss)
Earnings (Loss) Per Share [Policy Text Block]	i) Earnings (Loss) Per Share Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the quarters ended September 30, 2016 and 2015 because the inclusion of such underlying shares would have had an anti-dilutive effect.
Financial Instruments and Fair Value of Financial Instruments [Policy Text Block]	j) Financial Instruments and Fair Value of Financial Instruments • Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at September 30, 2016, the fair value of cash and restricted cash measured using Level 1 inputs. The Company’s financial instruments are cash, restricted cash, accounts payable and accrued liabilities and convertible debentures. The recorded values of cash and accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments.
Research and Development Costs [Policy Text Block]	k) Research and Development Costs
Fixed Assets [Policy Text Block]	l) Fixed Assets
Convertible debentures [Policy Text Block]	m) Convertible debentures
Modifications to debt [Policy Text Block]	n) Modifications to debt
Recently Adopted Accounting Pronouncements [Policy Text Block]	o) Recently Adopted Accounting Pronouncements In January 2015, the FASB issued ASU 2015-01, Income Statement-Extraordinary and Unusual Items (Subtopic 225-20), Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items, which eliminates the concept of extraordinary items. Under this new guidance, entities will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendments in this update are effective for annual and interim periods beginning after December 15, 2015. The Company adopted ASU 2015-01 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's interim consolidated financial position or results of operations. In February 2015, the FASB issued ASU No. 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis"("ASU 2015-02"). ASU 2015-02 makes several modifications to the consolidation guidance for variable interest entities ("VIEs") and general partners' investments in limited partnerships, as well as modifications to the evaluation of whether limited partnerships are VIEs or voting interest entities. It is effective for annual and interim periods beginning after December 15, 2015. Early adoption is permitted. The Company adopted ASU 2015-02 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's interim consolidated financial position or results of operations. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). In August 2015, FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (“ASU 2015-15”). ASU 2015-03 will require that debt issuance costs be presented in the balance sheet as a deduction from the carrying amount of the debt. ASU 2015-15 allows an entity to present debt issuance costs associated with a revolving line of credit arrangement as an asset, regardless of whether a balance is outstanding. The recognition and measurement guidance for debt issuance costs are not affected by ASU 2015-03 or ASU 2015-15. These ASU’s are effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period, with early adoption permitted. ASU 2015-03 will require the Company to reclassify its deferred financing costs associated with its long-term debt from other assets to long-term debt on a retrospective basis. The new standard will not affect the Company’s results of operations or cash flows. The Company adopted ASU 2015-15 on January 1, 2016 and the adoption of this pronouncement did not have a material effect on the Company's interim consolidated financial position or results of operations.
Recently Issued Accounting Pronouncements [Policy Text Block]	p) Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This accounting standard supersedes all existing US GAAP revenue recognition guidance. Under ASU 2014-09, a company will recognize revenue when it transfers the control of promised goods or services to customers in an amount that reflects the consideration which the company expects to collect in exchange for those goods or services. ASU 2014-09 will require additional disclosures in the notes to the consolidated financial statements and is effective for annual and interim reporting periods beginning after December 15, 2016. The Company is evaluating the impact of ASU 2014-09 and an estimate of the impact to the interim consolidated financial statements cannot be made at this time. On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting which amends ASC Topic 718, Compensation – Stock Compensation. The ASU simplifies several aspects of the accounting for employee share-based payment transactions. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is evaluating the impact of the amended guidance on its interim consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. The ASU provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessments of an entity's ability to continue as a going concern within one year of the date of issuance of the entity's financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is "substantial doubt about the entity's ability to continue as a going concern." The ASU is effective for annual periods ending after December 15, 2016, and interim periods thereafter and early adoption is permitted. The Company is evaluating the impact of ASU 2014-15 and an estimate of the impact to the interim consolidated financial statements cannot be made at this time. In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This accounting standard supersedes all existing US GAAP revenue recognition guidance. Under ASU 2014-09, a company will recognize revenue when it transfers the control of promised goods or services to customers in an amount that reflects the consideration which the company expects to collect in exchange for those goods or services. ASU 2014-09 will require additional disclosures in the notes to the consolidated financial statements and is effective for annual and interim reporting periods beginning after December 15, 2017. The Company is evaluating the impact of ASU 2014-09 and an estimate of the impact to the consolidated financial statements cannot be made at this time. On March 30, 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. The ASU simplifies several aspects of the accounting for employee share-based payment transactions. ASU 2016-09 is effective for public business entities for annual reporting periods beginning after December 15, 2016, and interim periods within that reporting period. Early adoption will be permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. The Company is evaluating the impact of the amended guidance on its consolidated financial statements. There have been no other accountings pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s financial position, results of operations or cash flows.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Property, Plant and Equipment [Table Text Block]	Cost Accumulated Net Book Value Amortization Furniture and Fixtures $ 1,833 $ - $ 1,833 Computer Equipment 24,782 3,769 21,013 Lab Equipment 45,448 2,429 43,019 Foreign Exchange Movement 2,708 242 2,466 Total as of September 30, 2016 $ 74,771 $ 6,440 $ 68,331 Computer Equipment $ 19,139 $ 3,769 $ 15,370 Lab Equipment 45,448 2,429 43,019 Foreign Exchange Movement (74 ) (6 ) (68 ) Total as of December 31, 2015 $ 64,513 $ 6,192 $ 58,321

Convertible debentures (Tables)

Convertible debentures (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Convertible Debt [Table Text Block]	September 30, 2016 December 31, 2015 Convertible debentures $ 1,040,503 $ 1,040,503 Convertible discount (852,418 ) (852,418 ) Net convertible debentures 188,085 188,085 Interest accretion 312,865 192,114 Balance, as at September 30, 2016 $ 500,950 380,199

Equity (Tables)

Equity (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 Expected life – yea 3 - 10 3 - 7 Interest rate 0.73 – 2.22% 0.97 – 2.09% Volatility 65.99 - 99.04% 62.86 – 94.97% Dividend yield - -% - -%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Options Weighted Expire date Average Exercise Price Balance, December 31, 2014 14,237,075 $ 0.01 Exercised, on June 23, 2015 (481,179 ) 0.01 Exercised, on June 25, 2015 (100,000 ) 0.01 Granted, on August 4, 2015 150,000 0.20 May 4, 2022 Granted, on August 7, 2015 1,610,000 0.20 August 7, 2022 Granted, on August 25, 2015 120,000 0.20 August 25, 2022 Granted, on September 1, 2015 150,000 0.20 September 1, 2022 Granted, on November 22, 2015 50,000 0.20 November 22, 2022 Granted, on December 1, 2015 125,000 0.20 December 1, 2022 Granted, on December 6, 2015 100,000 0.20 December 6, 2022 Balance, December 31, 2015 15,960,896 $ 0.04 Granted, on February 15, 2016 50,000 0.20 February 15, 2023 Granted, on March 7, 2016 75,000 0.20 March 7, 2023 Granted, on May 5, 2016 150,000 0.20 May 5, 2026 Granted, on June 6, 2016 800,000 0.20 June 6, 2021 Exercised, on July 7, 2016 (50,000 ) 0.01 Balance, September 30, 2016 16,985,896 $ 0.05
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Outstanding as at September 30, 2016 Exercisable as at September 30, 2016 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.92 9,750,000 $ 0.01 5.92 0.01 481,179 0.01 1.66 240,589 0.01 1.66 0.01 800,000 0.01 1.89 680,001 0.01 1.89 0.01 1,924,717 0.01 4.12 1,443,538 0.01 4.12 0.01 500,000 0.01 2.25 333,334 0.01 2.25 0.01 150,000 0.01 4.59 100,000 0.01 4.59 0.20 150,000 0.20 4.59 50,000 0.20 4.59 0.20 120,000 0.20 5.90 40,000 0.20 4.90 0.20 1,610,000 0.20 5.85 536,667 0.20 4.85 0.20 150,000 0.20 5.92 50,000 0.20 5.92 0.20 50,000 0.20 6.15 - - - 0.20 125,000 0.20 6.17 - - - 0.20 100,000 0.20 6.19 - - - 0.20 50,000 0.20 6.38 - - - 0.20 75,000 0.20 6.44 50,000 0.2 5.92 0.20 150,000 0.20 9.60 30,000 0.20 9.6 0.20 800,000 0.20 4.68 - - - 16,985,896 $ 0.05 5.25 13,254,129 $ 0.02 5.34	Outstanding as at December 31, 2015 Exercisable as at December 31, 2015 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 6.67 9,750,000 $ 0.01 6.67 0.01 481,179 0.01 2.41 - - - 0.01 800,000 0.01 2.64 453,334 0.01 2.64 0.01 1,924,717 0.01 4.87 1,443,538 0.01 4.87 0.01 500,000 0.01 3.01 333,334 0.01 3.01 0.01 150,000 0.01 5.35 50,000 0.01 5.35 0.01 50,000 0.01 3.37 - - - 0.20 150,000 0.20 5.35 - - - 0.20 120,000 0.20 6.65 - - - 0.20 1,610,000 0.20 6.61 - - - 0.20 150,000 0.20 6.67 50,000 0.20 6.67 0.20 50,000 0.20 6.90 - - - 0.20 125,000 0.20 6.92 - - - 0.20 100,000 0.20 6.94 - - - 15,960,896 $ 0.04 5.97 12,080,205 $ 0.01 6.20
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]	Number Amount of Shares Balance, December 31, 2013 13,209 $ 2,454,192 Issued for cash pursuant to share subscriptions 183 310,977 Balance, December 31, 2014 13,392 2,765,169 Issued for cash pursuant to share subscriptions 730 1,241,171 Shares issued to settle inter-company debts 203 345,198 Share subscription receivable (313 ) (532,084 ) Balance, December 31, 2015 14,012 $ 3,819,454 Shares issued to settle inter-company debts 639 1,086,018 Balance, September 30, 2016 14,651 4,905,472

Commitments And Guarantees (Tab

Commitments And Guarantees (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Consulting fee and Year Salaries Office rent Total 2016 $ 468,408 $ 37,824 $ 506,232 2017 312,272 37,824 350,096 2018 - 22,064 22,064 Total $ 780,680 $ 97,712 $ 878,392

Geographic Information (Tables)

Geographic Information (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Long-lived Assets by Geographic Areas [Table Text Block]	Nine month ended September 30, 2016 US Israel Total Long-live assets $ - $ 68,331 $ 68,331	Year ended December 31, 2015 US Israel Total Long-live assets $ - $ 58,321 $ 58,321

Restatement (Tables)

Restatement (Tables)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2015
Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block [Table Text Block]			As at June 30, 2015 (Unaudited) As Reported Adjustment As Restated $ $ $ Total Assets 1,910,811 1,910,811 Convertible debenture (Note 6) 1,257,522 (1,201,366 ) 56,156 Total Liabilities 1,496,543 (1,201,366 ) 295,177 Additional Paid-in Capital 8,360,774 (1,394,865 ) 6,965,909 (Deficit) Accumulated During the Development Stage (10,005,458 ) 2,596,231 (7,409,227 ) Equity Attributable to Shareholders of the Company 252,669 1,201,366 1,454,035 Total Equity 479,484 1,201,366 1,680,850 Total Liabilities and Equity 1,910,811 1,910,811	As at September 30, 2015 (Unaudited) As Reported Adjustment As Restated $ $ $ Total Assets 1,586,164 - 1,586,164 Convertible debenture (Note 6) 1,304,573 (1,180,438 ) 124,135 Total Liabilities 1,496,543 (1,180,438 ) 316,105 Additional Paid-in Capital 10,499,854 (1,394,865 ) 9,104,989 (Deficit) Accumulated During the Development Stage (10,413,168 ) 2,575,303 (7,837,865 ) Equity Attributable to Shareholders of the Company 81,505 1,180,438 1,261,943 Total Equity 89,621 1,180,438 1,270,059 Total Liabilities and Equity 1,586,164 - 1,586,164
Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block [Table Text Block]	Three months ended September 30, 2015 (Unaudited) As Reported Adjustment As Restated Other Expense Interest Expense (47,565 ) (20,928 ) (68,493 ) Net (Loss) for the period (407,709 ) (20,928 ) (428,637 ) Comprehensive Income (Loss) for the period (434,290 ) (20,928 ) (455,218 ) Net (Loss) attributable to: Common Stockholders (312,891 ) (76,716 ) (389,607 ) Non-Controlling Interests (94,818 ) 55,788 (39,030 ) (407,709 ) (20,928 ) (428,637 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (332,786 ) (76,716 ) (409,502 ) Non-Controlling Interests (101,504 ) 55,788 (45,716 ) (434,290 ) (20,928 ) (455,218 ) Basic and Diluted Net Loss per Common Share (0.05 ) (0.01 )	Three months ended June 30, 2015 (Unaudited) As Reported Adjustment As Restated General and Administrative Expenses $ Stock-Based Compensation 2,901,171 (2,621,965 ) 279,206 Other Expense Interest Expense (31,624 ) (25,734 ) (57,358 ) Net (Loss) for the period (3,785,016 ) 2,596,231 (1,188,785 ) Comprehensive Income (Loss) for the period (3,728,937 ) 2,596,231 (1,132,706 ) Net (Loss) attributable to: Common Stockholders (2,783,652 ) 1,786,179 (997,473 ) Non-Controlling Interests (1,001,364 ) 810,052 (191,312 ) (3,785,016 ) 2,596,231 (1,188,785 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (2,742,409 ) 1,785,548 (956,861 ) Non-Controlling Interests (986,528 ) 810,683 (175,845 ) (3,728,937 ) 2,596,231 (1,132,706 ) Basic and Diluted Net Loss per Common Share (0.04 ) (0.01 )	Six months ended June 30, 2015 (Unaudited) As Reported Adjustment As Restated General and Administrative Expenses $ Stock-Based Compensation 2,901,842 (2,621,966 ) 279,876 Other Expense Interest Expense (35,726 ) (25,735 ) (61,461 ) Net (Loss) for the period (4,120,551 ) 2,596,231 (1,524,320 ) Comprehensive Income (Loss) for the period (4,086,144 ) 2,596,231 (1,489,913 ) Net (Loss) attributable to: Common Stockholders (3,030,418 ) 1,731,854 (1,298,564 ) Non-Controlling Interests (1,090,133 ) 864,377 (225,756 ) (4,120,551 ) 2,596,231 (1,524,320 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (3,005,113 ) 1,731,467 (1,273,646 ) Non-Controlling Interests (1,081,031 ) 864,764 (216,267 ) (4,086,144 ) 2,596,231 (1,489,913 ) Basic and Diluted Net Loss per Common Share (0.05 ) - (0.02 )	Nine months ended September 30, 2015 (Unaudited) As Reported Adjustment As Restated General and Administrative Expenses $ Stock-Based Compensation 2,946,268 (2,621,966 ) 324,302 Other Expense Interest Expense (83,292 ) (46,663 ) (129,955 ) Net (Loss) for the period (4,528,261 ) 2,575,303 (1,952,958 ) Comprehensive Income (Loss) for the period (4,520,433 ) 2,575,303 (1,945,130 ) Net (Loss) attributable to: Common Stockholders (3,397,021 ) 1,693,051 (1,703,970 ) Non-Controlling Interests (1,131,240 ) 882,252 (248,988 ) (4,528,261 ) 2,575,303 (1,952,958 ) Net Comprehensive Income (Loss) Attributable to: Common Stockholders (3,391,161 ) 1,693,051 (1,698,110 ) Non-Controlling Interests (1,129,272 ) 882,252 (247,020 ) (4,520,433 ) 2,575,303 (1,945,130 ) Basic and Diluted Net Loss per Common Share (0.05 ) (0.02 )

Nature of Operations and Goin24

Nature of Operations and Going Concern (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)shares
Nature Of Operations And Going Concern 1	100.00%
Nature Of Operations And Going Concern 2 | shares	16,000,000
Nature Of Operations And Going Concern 3	89.00%
Nature Of Operations And Going Concern 4	$ 10
Nature Of Operations And Going Concern 5	430
Nature Of Operations And Going Concern 6	386,579
Nature Of Operations And Going Concern 7	1,104,876
Nature Of Operations And Going Concern 8	$ 9,483,096

Significant Accounting Polici25

Significant Accounting Policies (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)yr
Significant Accounting Policies 1	85.78%
Significant Accounting Policies 2	77.00%
Significant Accounting Policies 3	75.02%
Significant Accounting Policies 4 | $	$ 4,787
Significant Accounting Policies 5	3
Significant Accounting Policies 6 | yr	15

License and Research Funding 26

License and Research Funding Agreement (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)d$ / sharesshares
License And Research Funding Agreement 1	$ 1,600,000
License And Research Funding Agreement 2	$ 81,000
License And Research Funding Agreement 3 | d	5
License And Research Funding Agreement 4	$ 359,500
License And Research Funding Agreement 5	359,500
License And Research Funding Agreement 6	400,000
License And Research Funding Agreement 7	$ 400,000
License And Research Funding Agreement 8	15.00%
License And Research Funding Agreement 9	1,765
License And Research Funding Agreement 10	$ 1,698.97
License And Research Funding Agreement 11	$ 2,998,682
License And Research Funding Agreement 12 | shares	1,765
License And Research Funding Agreement 13 | $ / shares	$ 1,698.97
License And Research Funding Agreement 14	$ 28,050
License And Research Funding Agreement 15	$ 723,721

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Related Party Transactions 1	$ 450,726
Related Party Transactions 2	$ 24,300
Related Party Transactions 3	0
Related Party Transactions 4	$ 121,842
Related Party Transactions 5	16,325
Related Party Transactions 6	$ 74,062
Related Party Transactions 7	10.00%

Convertible debentures (Narrati

Convertible debentures (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Convertible Debentures 1	$ 852,418
Convertible Debentures 2	0.055
Convertible Debentures 3	188,085
Convertible Debentures 4	0.20
Convertible Debentures 5	$ 852,418
Convertible Debentures 6	77.00%
Convertible Debentures 7	$ 120,751
Convertible Debentures 8	$ 77,472

Equity (Narrative) (Details)

Equity (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)yr$ / sharesshares
Equity 1 | shares	3,550,000
Equity 2 | $ / shares	$ 0.20
Equity 3	$ 710,000
Equity 4 | shares	500,000
Equity 5 | $ / shares	$ 0.20
Equity 6	$ 100,000
Equity 7	$ 74,062
Equity 8 | shares	462,890
Equity 9 | $ / shares	$ 0.20
Equity 10 | shares	481,179
Equity 11 | $ / shares	$ 0.01
Equity 12	$ 4,812
Equity 13 | shares	100,000
Equity 14 | $ / shares	$ 0.01
Equity 15	$ 1,000
Equity 16 | shares	5,000,000
Equity 17 | $ / shares	$ 0.20
Equity 18	$ 1,000,000
Equity 19 | shares	3,824,922
Equity 20 | $ / shares	$ 0.16
Equity 21	80.00%
Equity 22	$ 611,987
Equity 23 | shares	1,786,250
Equity 24 | $ / shares	$ 0.16
Equity 25	80.00%
Equity 26	$ 285,800
Equity 27 | shares	637,500
Equity 28 | $ / shares	$ 0.16
Equity 29	80.00%
Equity 30	$ 102,000
Equity 31 | shares	1,756,619
Equity 32 | $ / shares	$ 0.16
Equity 33	80.00%
Equity 34	$ 281,059
Equity 35 | shares	2,198,819
Equity 36 | $ / shares	$ 0.16
Equity 37	80.00%
Equity 38	$ 351,811
Equity 39 | shares	318,742
Equity 40 | $ / shares	$ 0.16
Equity 41	80.00%
Equity 42	$ 50,999
Equity 43 | shares	625,000
Equity 44 | $ / shares	$ 0.20
Equity 45	$ 125,000
Equity 46 | shares	824,992
Equity 47 | $ / shares	$ 0.16
Equity 48	80.00%
Equity 49	$ 131,999
Equity 50 | shares	318,749
Equity 51 | $ / shares	$ 0.16
Equity 52	80.00%
Equity 53	$ 50,999
Equity 54 | shares	1,115,625
Equity 55 | $ / shares	$ 0.16
Equity 56	80.00%
Equity 57	$ 178,500
Equity 58 | shares	2,500,000
Equity 59 | $ / shares	$ 0.20
Equity 60	$ 500,000
Equity 61 | shares	50,000
Equity 62 | $ / shares	$ 0.01
Equity 63	$ 500
Equity 64 | shares	839,375
Equity 65 | $ / shares	$ 0.16
Equity 66	80.00%
Equity 67	$ 134,300
Equity 68 | shares	4,653,732
Equity 69 | $ / shares	$ 0.16
Equity 70	80.00%
Equity 71	$ 744,597
Equity 72	$ 15,000
Equity 73 | shares	114,180,828
Equity 74 | shares	20,000,000
Equity 75 | $ / shares	$ 0.001
Equity 76 | shares	962,358
Equity 77 | $ / shares	$ 0.01
Equity 78	481,179
Equity 79 | $ / shares	$ 0.01
Equity 80	$ 4,812
Equity 81	14,752
Equity 82	$ 106,159
Equity 83 | shares	800,000
Equity 84 | $ / shares	$ 0.01
Equity 85	480,000
Equity 86 | shares	320,000
Equity 87	600
Equity 88 | yr	4
Equity 89	50
Equity 90	$ 33,189
Equity 91	$ 18,827
Equity 92 | shares	1,924,717
Equity 93 | $ / shares	$ 0.01
Equity 94	$ 22,934
Equity 95	$ 141,156
Equity 96 | shares	500,000
Equity 97 | $ / shares	$ 0.01
Equity 98	$ 7,910
Equity 99	$ 0
Equity 100 | shares	150,000
Equity 101 | $ / shares	$ 0.01
Equity 102	$ 174
Equity 103	$ 982
Equity 104 | shares	150,000
Equity 105 | $ / shares	$ 0.01
Equity 106	25,000
Equity 107	75,000
Equity 108	50,000
Equity 109	$ 0
Equity 110	$ 24,017
Equity 111	100,000
Equity 112 | $ / shares	$ 0.01
Equity 113	$ 1,000
Equity 114	50,000
Equity 115 | $ / shares	$ 0.01
Equity 116	$ 500
Equity 117 | shares	150,000
Equity 118 | $ / shares	$ 0.20
Equity 119	$ 7,397
Equity 120 | shares	1,730,000
Equity 121 | $ / shares	$ 0.20
Equity 122	$ 98,785
Equity 123 | shares	150,000
Equity 124 | $ / shares	$ 0.20
Equity 125	$ 12,952
Equity 126 | shares	50,000
Equity 127 | $ / shares	$ 0.20
Equity 128	$ 3,114
Equity 129 | shares	125,000
Equity 130 | $ / shares	$ 0.20
Equity 131	$ 7,958
Equity 132 | shares	100,000
Equity 133 | $ / shares	$ 0.20
Equity 134	$ 7,047
Equity 135 | shares	50,000
Equity 136 | $ / shares	$ 0.20
Equity 137	$ 2,062
Equity 138 | shares	75,000
Equity 139 | $ / shares	$ 0.20
Equity 140	$ 2,966
Equity 141 | shares	150,000
Equity 142 | $ / shares	$ 0.20
Equity 143	$ 3,485
Equity 144 | shares	800,000
Equity 145 | $ / shares	$ 0.20
Equity 146	480,000
Equity 147 | shares	320,000
Equity 148	600
Equity 149 | yr	4
Equity 150	50
Equity 151	$ 9,814
Equity 152 | shares	1,765
Equity 153	15.00%
Equity 154 | shares	592
Equity 155 | $ / shares	$ 1,698.97
Equity 156	4.79%
Equity 157	$ 1,005,795
Equity 158	80.00%
Equity 159	$ 500,000
Equity 160	$ 30,000,000
Equity 161 | shares	684
Equity 162 | $ / shares	$ 1,698.97
Equity 163	5.11%
Equity 164	$ 1,162,192
Equity 165 | shares	760
Equity 166 | $ / shares	$ 1,700
Equity 167	5.68%
Equity 168	$ 1,292,000
Equity 169 | shares	183
Equity 170 | $ / shares	$ 1,699
Equity 171	1.37%
Equity 172	$ 310,977
Equity 173 | shares	417
Equity 174 | $ / shares	$ 1,700
Equity 175	$ 709,087
Equity 176 | shares	516
Equity 177	$ 1,700
Equity 178	$ 532,084
Equity 179 | shares	588
Equity 180	6,248,672
Equity 181	77.00%
Equity 182	12.60%
Equity 183	10.40%
Equity 184	74.67%
Equity 185	13.18%
Equity 186	12.15%
Equity 187 | shares	1,132
Equity 188	12,026,652
Equity 189	$ 1,086,018
Equity 190 | shares	639
Equity 191	85.78%
Equity 192	12.01%
Equity 193	2.21%
Equity 194	77.00%
Equity 195	12.60%
Equity 196	10.40%
Equity 197 | shares	1,765
Equity 198 | $ / shares	$ 1,698.97

Commitments And Guarantees (Nar

Commitments And Guarantees (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)yrshares
Commitments And Guarantees 1	$ 250,000
Commitments And Guarantees 2 | shares	3,750,000
Commitments And Guarantees 3	$ 0.01
Commitments And Guarantees 4 | yr	10
Commitments And Guarantees 5	$ 112,324
Commitments And Guarantees 6	432,000
Commitments And Guarantees 7 | shares	2,750,000
Commitments And Guarantees 8	$ 0.01
Commitments And Guarantees 9 | yr	10
Commitments And Guarantees 10	$ 106,084
Commitments And Guarantees 11	408,000
Commitments And Guarantees 12 | shares	2,000,000
Commitments And Guarantees 13	$ 0.01
Commitments And Guarantees 14 | yr	10
Commitments And Guarantees 15 | yr	2
Commitments And Guarantees 16	$ 3,152
Commitments And Guarantees 17	12,121
Commitments And Guarantees 18	$ 89,966
Commitments And Guarantees 19	339,388
Commitments And Guarantees 20	$ 13,254
Commitments And Guarantees 21	50,000

Subsequent Event (Narrative) (D

Subsequent Event (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Subsequent Event 1	360,000
Subsequent Event 2	$ 0.20
Subsequent Event 3	180,000

Schedule of Property, Plant and

Schedule of Property, Plant and Equipment (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 1	$ 1,833
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 2	0
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 3	1,833
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 4	24,782
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 5	3,769
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 6	21,013
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 7	45,448
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 8	2,429
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 9	43,019
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 10	2,708
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 11	242
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 12	2,466
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 13	74,771
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 14	6,440
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 15	68,331
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 16	19,139
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 17	3,769
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 18	15,370
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 19	45,448
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 20	2,429
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 21	43,019
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 22	(74)
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 23	(6)
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 24	(68)
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 25	64,513
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 26	6,192
Property, Plant And Equipment Schedule Of Property, Plant And Equipment 27	$ 58,321

Schedule of Convertible Debt (D

Schedule of Convertible Debt (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Convertible Debentures Schedule Of Convertible Debt 1	$ 1,040,503
Convertible Debentures Schedule Of Convertible Debt 2	1,040,503
Convertible Debentures Schedule Of Convertible Debt 3	(852,418)
Convertible Debentures Schedule Of Convertible Debt 4	(852,418)
Convertible Debentures Schedule Of Convertible Debt 5	188,085
Convertible Debentures Schedule Of Convertible Debt 6	188,085
Convertible Debentures Schedule Of Convertible Debt 7	312,865
Convertible Debentures Schedule Of Convertible Debt 8	192,114
Convertible Debentures Schedule Of Convertible Debt 9	500,950
Convertible Debentures Schedule Of Convertible Debt 10	$ 380,199

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1	$ 3
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2	10
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3	3
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4	$ 7
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5	0.73
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6	2.22%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7	0.97
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8	2.09%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9	65.99
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10	99.04%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11	62.86
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12	94.97%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13	0.00%
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14	0.00%

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 1	$ 14,237,075
Equity Schedule Of Share-based Compensation, Stock Options, Activity 2	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 3	$ (481,179)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 4	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 5	$ (100,000)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 6	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 7	$ 150,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 8	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 9	$ 1,610,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 10	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 11	$ 120,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 12	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 13	$ 150,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 14	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 15	$ 50,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 16	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 17	$ 125,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 18	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 19	$ 100,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 20	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 21	$ 15,960,896
Equity Schedule Of Share-based Compensation, Stock Options, Activity 22	0.04
Equity Schedule Of Share-based Compensation, Stock Options, Activity 23	$ 50,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 24	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 25	$ 75,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 26	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 27	$ 150,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 28	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 29	$ 800,000
Equity Schedule Of Share-based Compensation, Stock Options, Activity 30	0.20
Equity Schedule Of Share-based Compensation, Stock Options, Activity 31	$ (50,000)
Equity Schedule Of Share-based Compensation, Stock Options, Activity 32	0.01
Equity Schedule Of Share-based Compensation, Stock Options, Activity 33	$ 16,985,896
Equity Schedule Of Share-based Compensation, Stock Options, Activity 34	0.05

Schedule of Disclosure of Share

Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2016USD ($)	Dec. 31, 2015USD ($)
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	$ 481,179
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	1.66
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	$ 240,589
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	1.66
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	$ 800,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	1.89
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	$ 680,001
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	1.89
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	$ 1,924,717
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	4.12
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	$ 1,443,538
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	4.12
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	$ 500,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	2.25
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	$ 333,334
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	2.25
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39	4.59
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40	$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41	0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42	4.59
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46	4.59
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49	4.59
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51	$ 120,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53	5.90
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54	$ 40,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56	4.90
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58	$ 1,610,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60	5.85
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61	$ 536,667
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63	4.85
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74	6.15
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79	$ 125,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81	6.17
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86	$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88	6.19
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95	6.38
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100	$ 75,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102	6.44
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103	$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104	0.2
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 105	5.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 106	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 107	$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 108	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 109	9.60
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 110	$ 30,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 111	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 112	9.6
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 113	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 114	$ 800,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 115	0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 116	4.68
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 117	$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 118	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 119	0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 120	$ 16,985,896
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 121	0.05
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 122	5.25
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 123	$ 13,254,129
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 124	0.02
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 125	5.34
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2		$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5		$ 9,750,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9		$ 481,179
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11		2.41
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16		$ 800,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18		2.64
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19		$ 453,334
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21		2.64
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23		$ 1,924,717
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25		4.87
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26		$ 1,443,538
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28		4.87
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30		$ 500,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32		3.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33		$ 333,334
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35		3.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37		$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39		5.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42		5.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46		3.37
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51		$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53		5.35
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58		$ 120,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60		6.65
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65		$ 1,610,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67		6.61
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72		$ 150,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77		6.67
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79		$ 50,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81		6.90
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86		$ 125,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88		6.92
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93		$ 100,000
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94		0.20
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95		6.94
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96		$ 0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98		0
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99		$ 15,960,896
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100		0.04
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101		5.97
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102		$ 12,080,205
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103		0.01
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104		6.20

Consolidation, Less than Wholly

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 1	$ 13,209
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 2	2,454,192
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 3	183
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 4	310,977
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 5	13,392
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 6	2,765,169
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 7	730
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 8	1,241,171
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 9	203
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 10	345,198
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 11	(313)
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 12	(532,084)
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 13	14,012
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 14	3,819,454
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 15	639
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 16	1,086,018
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 17	14,651
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 18	$ 4,905,472

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments for Operating Leases (Details)	9 Months Ended
	Sep. 30, 2016USD ($)
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 1	$ 468,408
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 2	37,824
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 3	506,232
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 4	312,272
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 5	37,824
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 6	350,096
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 7	0
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 8	22,064
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 9	22,064
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 10	780,680
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 11	97,712
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 12	$ 878,392

Long-lived Assets by Geographic

Long-lived Assets by Geographic Areas (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Geographic Information Long-lived Assets By Geographic Areas 1	$ 0
Geographic Information Long-lived Assets By Geographic Areas 2	68,331
Geographic Information Long-lived Assets By Geographic Areas 3	$ 68,331
Geographic Information Long-lived Assets By Geographic Areas 1		$ 0
Geographic Information Long-lived Assets By Geographic Areas 2		58,321
Geographic Information Long-lived Assets By Geographic Areas 3		$ 58,321

Schedule Of Error Corrections A

Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block (Details) - USD ($)	6 Months Ended	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2015
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 1	$ 1,910,811
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 2	1,910,811
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 3	1,257,522
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 4	(1,201,366)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 5	56,156
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 6	1,496,543
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 7	(1,201,366)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 8	295,177
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 9	8,360,774
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 10	(1,394,865)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 11	6,965,909
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 12	(10,005,458)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 13	2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 14	(7,409,227)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 15	252,669
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 16	1,201,366
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 17	1,454,035
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 18	479,484
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 19	1,201,366
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 20	1,680,850
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 21	1,910,811
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 22	$ 1,910,811
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 1		$ 1,586,164
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 2		0
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 3		1,586,164
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 4		1,304,573
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 5		(1,180,438)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 6		124,135
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 7		1,496,543
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 8		(1,180,438)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 9		316,105
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 10		10,499,854
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 11		(1,394,865)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 12		9,104,989
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 13		(10,413,168)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 14		2,575,303
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 15		(7,837,865)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 16		81,505
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 17		1,180,438
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 18		1,261,943
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 19		89,621
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 20		1,180,438
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 21		1,270,059
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 22		1,586,164
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 23		0
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Consolidated Balance Sheets Table Text Block 24		$ 1,586,164

Schedule Of Error Corrections41

Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block (Details)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2015USD ($)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 1		$ 2,901,171
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 2		(2,621,965)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 3		279,206
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 4		(31,624)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 5		(25,734)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 6		(57,358)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 7		(3,785,016)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 8		2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 9		(1,188,785)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 10		(3,728,937)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 11		2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 12		(1,132,706)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 13		(2,783,652)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 14		1,786,179
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 15		(997,473)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 16		(1,001,364)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 17		810,052
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 18		(191,312)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 19		(3,785,016)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 20		2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 21		(1,188,785)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 22		(2,742,409)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 23		1,785,548
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 24		(956,861)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 25		(986,528)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 26		810,683
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 27		(175,845)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 28		(3,728,937)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 29		2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 30		$ (1,132,706)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 31		(0.04)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 32		(0.01)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 1			$ 2,901,842
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 2			(2,621,966)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 3			279,876
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 4			(35,726)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 5			(25,735)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 6			(61,461)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 7			(4,120,551)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 8			2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 9			(1,524,320)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 10			(4,086,144)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 11			2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 12			(1,489,913)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 13			(3,030,418)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 14			1,731,854
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 15			(1,298,564)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 16			(1,090,133)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 17			864,377
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 18			(225,756)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 19			(4,120,551)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 20			2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 21			(1,524,320)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 22			(3,005,113)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 23			1,731,467
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 24			(1,273,646)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 25			(1,081,031)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 26			864,764
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 27			(216,267)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 28			(4,086,144)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 29			2,596,231
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 30			$ (1,489,913)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 31			(0.05)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 32			$ 0
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 33			(0.02)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 1	$ (47,565)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 2	(20,928)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 3	(68,493)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 4	(407,709)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 5	(20,928)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 6	(428,637)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 7	(434,290)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 8	(20,928)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 9	(455,218)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 10	(312,891)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 11	(76,716)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 12	(389,607)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 13	(94,818)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 14	55,788
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 15	(39,030)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 16	(407,709)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 17	(20,928)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 18	(428,637)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 19	(332,786)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 20	(76,716)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 21	(409,502)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 22	(101,504)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 23	55,788
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 24	(45,716)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 25	(434,290)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 26	(20,928)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 27	$ (455,218)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 28	(0.05)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 29	(0.01)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 1				$ 2,946,268
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 2				(2,621,966)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 3				324,302
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 4				(83,292)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 5				(46,663)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 6				(129,955)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 7				(4,528,261)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 8				2,575,303
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 9				(1,952,958)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 10				(4,520,433)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 11				2,575,303
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 12				(1,945,130)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 13				(3,397,021)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 14				1,693,051
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 15				(1,703,970)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 16				(1,131,240)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 17				882,252
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 18				(248,988)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 19				(4,528,261)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 20				2,575,303
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 21				(1,952,958)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 22				(3,391,161)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 23				1,693,051
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 24				(1,698,110)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 25				(1,129,272)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 26				882,252
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 27				(247,020)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 28				(4,520,433)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 29				2,575,303
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 30				$ (1,945,130)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 31				(0.05)
Restatement Schedule Of Error Corrections And Prior Period Adjustments In Statement Of Operations Table Text Block 32				(0.02)